News | September 24, 2008

Clinical Data Shows Rheos Therapy Improves Heart Structure, Function in Early-Stage HF Patients

September 25, 2008- The use of the CVRx Rheos System in treating early-stage heart failure patients shows Rheos Therapy significantly improved heart structure and function, according to clinical data presented this week by John D. Bisognano, M.D, Ph.D., associate professor of medicine at the University of Rochester School of Medicine and Dentistry, New York, at the Heart Failure Society of America (HFSA) 12th Annual Scientific Meeting in Toronto.
In heart failure patients, the heart becomes enlarged and functions inefficiently, increasing the risk of death and poor quality of life. Reducing heart size lowers these risks.
The clinical data showed that continuous use of Rheos Therapy in early-stage heart failure patients remodels cardiac structure and improves heart function. The Rheos System was implanted in 18 patients at five medical centers in Europe and the U.S who had early-stage heart failure and high blood pressure, and who were on optimal medication levels. After one year of Rheos therapy, left ventricular mass and left atrial dimension were reduced toward normal levels, and blood pressure was lowered.
“We believe the Rheos System can have significant therapeutic value in heart failure patients,” said Dr. Bisognano. “The current clinical trial evaluating the Rheos System will help us further understand how Rheos Therapy addresses heart failure.” The first study evaluating Rheos Therapy in diastolic heart failure patients has begun in Europe.
The Rheos System uses the CVRx-patented Baroreflex Activation Therapy technology that is designed to activate the carotid baroreceptors, central components of the body’s natural cardiovascular regulation system. When the baroreceptors are activated, signals are sent through neural pathways to the brain and interpreted as a rise in blood pressure. The brain works to counteract this perceived rise in blood pressure by sending signals to other parts of the body (heart, blood vessels and kidneys) that relax the blood vessels and inhibit the production of stress-related hormones. These changes enable the heart to increase blood output, while maintaining or reducing its workload, thereby reducing blood pressure when it is elevated and alleviating the symptoms of heart failure.
The Rheos System is comprised of a small pulse generator implanted under the collar bone; two thin lead wires implanted at the left and right carotid arteries and connected to the pulse generator; and the Rheos Programmer System, an external device used by doctors to noninvasively regulate the activation energy from the generator to the lead wires.
For more information:

Related Content

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Overlay Init